leisure time -WSS

leisure time

author：fashion 2025-08-26 23:44:05 - browse：82

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout LOUD podcast: ESMO highlights & Roivant's big deal

WSS

Medicare proceeds with plan to claw back hospital funds

Microbiome research is starting to find links to chronic diseases

Medical student insurance fails on mental health care coverage

STAT Virtual Event: Putting AI to the Test

CDC advisers recommend seasonal use of Pfizer RSV shot

Kidney transplant patients stopped immunosuppressants in trial

entertainment

leisure time

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Experts study whether long Covid risk adds up with each reinfection

Heart attack and stroke risk calculators need revising

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

At least 13 dead in Texas as scorching temps continue

Thermo Fisher plant for manufacturing gene therapies to expand

BioMarin wins approval for gene therapy to treat hemophilia A

Humans aren't the only ones with an imagination. Rats have it too

How one medical school became remarkably diverse

Thermo Fisher plant for manufacturing gene therapies to expand

focus

After Sarepta trial failure, Duchenne families brace for more debate

CDC's new outbreak response network to include Northeastern

https://cbu01.alicdn.com/img/ibank/2017/201/490/4512094102_1983532679.220x220xz.jpg

How AI helped researchers track recovery from depression

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

CommonSpirit Health keeps growing, even as it loses money

explore

focus

hotspot

focus